News - MedTech & Diagnostics
What Philips’ new report adds to the ‘AI in healthcare’ debate

Ten years in, the Future Health Index (FHI) lands with sharp relevance – less a forecast, more a mirror. In a healthcare system grappling with the promises and pitfalls of artificial intelligence (AI), Shehaan Fernando, Interim Managing Director of Philips ANZ, joins the Health Industry Hub podcast to unpack what the latest data reveals.
Three government-led consultations on AI in healthcare have taken place in just the past year, culminating in a Department of Health report released in July. So, what additional value does the FHI report bring to the ongoing debate?
From workforce readiness to ethical grey zones, and from patient trust to policy ambition, this conversation delves into the themes that define how we use AI “to bend the cost curve”. It also dares to confront a more uncomfortable insight that is essential for healthcare leaders to face.
With the re-elected Labor government likely to remain in power for the next six years, the window to move from talk to action is wide open. Navigating what’s next will demand more than algorithms – it will demand backbone for sustainable implementation so that we can finally move beyond the cycle of ‘more pilots than Qantas’.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News - MedTech & Diagnostics
‘Get comfortable being uncomfortable,’ urges Medtronic VP and Managing Director
The leadership compass is being recalibrated as the old coordinates give way to complexity, contradiction and change. For Liz Carnabuci, […]
MoreNews - MedTech & Diagnostics
Department of Health halts PL changes as industry warns of device viability
The Department of Health has received the final evaluation report into the Prescribed List (PL) reforms from the Nous Group, […]
MoreNews - Biotechnology
argenx inks new agreement with Australian regenerative medicine biotech
Immunology company argenx has entered into a new strategic partnership agreement with Monash University and Monash-originated spinout Myostellar, to develop […]
MoreNews - Pharmaceuticals
The human face rewriting Australia’s most common rare disease, cystic fibrosis
New national data from the Australian Cystic Fibrosis Data Registry (ACFDR) has revealed a significant shift in the trajectory of […]
More